Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study
NCT ID: NCT06487013
Last Updated: 2024-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2023-12-08
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of ArcBlate MRgHIFU in Patients With Painful Bone Metastases: An Extension Study
NCT06487026
A Safety Evaluation of MR-guided Focused Ultrasound Treatment for Palliative Pain Control of Bone Metastases
NCT03086824
MR Guided Focused Ultrasound vs Radiotherapy for Palliative Pain Tx in Bone Metastases
NCT05250687
Antalgic Treatment of Painful Bone Metastases by US-guided High Intensity Focused Ultrasound (HIFU)
NCT01765907
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
NCT01091883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MRgHIFU treatment arm
Subjects will be randomized to MRgHIFU treatment arm and will pass the Screening Fail criteria preceded in normal fashion to MRgHIFU treatment at the same session.
ArcBlate Focused Ultrasound Ablation System
MR-guided High Intensity Focused Ultrasound (MRgHIFU)
Sham treatment arm
Subjects who will be randomized to sham treatment arm and passed the Screening Fail Criteria (i.e. MRI Screening and Sonication Screening) will undergo a sham MRgHIFU treatment with sonication energy disabled.
Sham MRgHIFU treatment
Sham MRgHIFU treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ArcBlate Focused Ultrasound Ablation System
MR-guided High Intensity Focused Ultrasound (MRgHIFU)
Sham MRgHIFU treatment
Sham MRgHIFU treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Men and women aged 18 and older.
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at enrollment.
3. Patients who are able and willing to give consent and able to attend all study visits.
4. Patients who are suffering from painful bone metastases.
5. Patients who refuse other accepted available treatments such as surgery or radiotherapy for pain palliation.
6. Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication.
7. Able to communicate sensations during the ArcBlate MRgHIFU treatment.
8. Patients on ongoing systemic anticancer treatment for at least 2 weeks before treatment:
* with same systemic anticancer treatment (as documented from patient medical dossier), And
* worst pain NRS still ≥ 4, And
* do NOT plan to initiate a new chemotherapy for pain palliation throughout the study duration.
(9) No radiation therapy to targeted (most painful) lesion in the past two weeks before treatment.
(10) Bisphosphonate intake should remain stable throughout the study duration. (11) Patients will have from 1 to 5 painful lesions and only the most painful lesion will be treated.
(12) Patients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated).
* MRI Screening (Screening 2):
1. Targeted tumor(s) are ArcBlate MRgHIFU accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5).
2. Patient whose targeted (treated) lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin.
3. Targeted (treated) tumor clearly visible by non-contrast MRI, and ArcBlate MRgHIFU accessible.
* Sonication Screening (Screening 3):
1. Subjects could tolerate planned test sonications per randomized treatment.
Exclusion Criteria
(1) Patients who either
* need surgical stabilization of the affected bony structure (\>7 fracture risk score), Or
* targeted tumor is at an impending fracture site (\>7 on fracture risk score), Or
* patients with surgical stabilization of tumor site with metallic hardware. (2) Targeted (treated) lesion is in the skull. (3) Patients on dialysis. (4) Patients with life expectancy \< 3-Months. (5) Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.
(6) Patients with unstable cardiac status including:
* Unstable angina pectoris on medication,
* Patients with documented myocardial infarction within six months of protocol entry,
* Congestive heart failure requiring medication (other than diuretic),
* Patients on anti-arrhythmic drugs. (7) Severe hypertension (diastolic blood pressure \> 100 mmHg on medication). (8) Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations (unable to fit into ArcBlate MRgHIFU), etc.
(9) Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.
(10) Known intolerance or allergies to the MRI contrast agent (e.g., Gadolinium or Magnevist) and Computed Tomography (CT) contrast agent including advanced kidney disease.
(11) Severe cerebrovascular disease (multiple CerebroVascular Accident (CVA) or CVA within 6 months).
(12) Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.).
(13) Are participating or have participated in another clinical trial in the last 30 days.
(14) Patients initiating a new chemotherapy regime, or radiation (for the targeted most painful lesion) within the last 2 weeks before treatment.
(15) Patients unable to communicate with the investigator and staff. (16) Patients with persistent undistinguishable pain (pain source unidentifiable).
(17) The targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.
(18) Patients with calcified treatment area. (19) Pregnant women.
* MRI Screening (Screening 2):
1. Target (treated) lesion is less than 10-mm from nerve bundles, bowels or bladder.
2. Extensive scarring in the energy path of the planned treatment area
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EpiSonica
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Far Eastern Memorial Hospital
New Taipei City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital - Linkou
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTP-BM-22-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.